Transcatheter Aortic Valve Replacement in Degenerated Perceval Bioprosthesis: Clinical and Technical Aspects in 32 Cases
Journal of Clinical Medicine · 28.09.2023 · 12 (19) · 6265
DOI: 10.3390/jcm12196265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.09.2023. Verfasst von Giovanni Concistrè und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Adult Cardiac Surgery, G. Pasquinucci Heart Hospital, Fondazione CNR-G. Monasterio, 54100 Massa, Italy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sutureless aortic bioprostheses are increasingly being used to provide shorter cross-clamp time and facilitate minimally invasive aortic valve replacement. As the use of sutureless valves has increased over the past decade, we begin to encounter their degeneration. We describe clinical outcomes and technical aspects in patients with degenerated sutureless Perceval (CorCym, Italy) aortic bioprosthesis treated with valve-in-valve transcatheter aortic valve replacement (VIV-TAVR).
Methods
Between March 2011 and March 2023, 1310 patients underwent aortic valve replacement (AVR) with Perceval bioprosthesis implantation. Severe bioprosthesis degeneration treated with VIV-TAVR occurred in 32 patients with a mean of 6.4 ± 1.9 years (range: 2–10 years) after first implantation. Mean EuroSCORE II was 9.5 ± 6.4% (range: 1.9–35.1%).
Results
Thirty of thirty-two (94%) VIV-TAVR were performed via transfemoral and two (6%) via transapical approach. Vascular complications occurred in two patients (6%), and mean hospital stay was 4.6 ± 2.4 days. At mean follow-up of 16.7 ± 15.2 months (range: 1–50 months), survival was 100%, and mean transvalvular pressure gradient was 18.7 ± 5.3 mmHg.
Conclusion
VIV-TAVR is a useful option for degenerated Perceval and appears safe and effective. This procedure is associated with good clinical results and excellent hemodynamic performance in our largest single-center experience.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Adult Cardiac Surgery, G. Pasquinucci Heart Hospital, Fondazione CNR-G. Monasterio, 54100 Massa, Italy.
- Department of Cardiology, G. Pasquinucci Heart Hospital, Fondazione CNR-G. Monasterio, 54100 Massa, Italy.
ORCID-Profile: Tommaso Gasbarri, Giacomo Bianchi, Rafik Margaryan, Sergio Berti
Zitieren
APA
Concistrè, G., Gasbarri, T., Ravani, M., Al Jabri, A., Trianni, G., Bianchi, G., Margaryan, R., Chiaramonti, F., Murzi, M., Kallushi, E., Varone, E., Simeoni, S., Leone, A., Farneti, A., Berti, S., & Solinas, M. (2023). Transcatheter Aortic Valve Replacement in Degenerated Perceval Bioprosthesis: Clinical and Technical Aspects in 32 Cases. Journal of Clinical Medicine, 12(19), 6265. https://doi.org/10.3390/jcm12196265
Vancouver
Concistrè G, Gasbarri T, Ravani M, Al Jabri A, Trianni G, Bianchi G, et al. Transcatheter Aortic Valve Replacement in Degenerated Perceval Bioprosthesis: Clinical and Technical Aspects in 32 Cases. Journal of Clinical Medicine. 2023;12(19):6265. doi:10.3390/jcm12196265
BibTeX
@article{Concistr2023,
author = {Concistrè, Giovanni and Gasbarri, Tommaso and Ravani, Marcello and Al Jabri, Anees and Trianni, Giuseppe and Bianchi, Giacomo and Margaryan, Rafik and Chiaramonti, Francesca and Murzi, Michele and Kallushi, Enkel and Varone, Egidio and Simeoni, Simone and Leone, Alessandro and Farneti, Andrea and Berti, Sergio and Solinas, Marco},
title = {Transcatheter Aortic Valve Replacement in Degenerated Perceval Bioprosthesis: Clinical and Technical Aspects in 32 Cases},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {19},
pages = {6265},
doi = {10.3390/jcm12196265}
}
EUVIMED